Skip to main content

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Date Title
Toggle Summary Sienna Biopharmaceuticals Establishes Corporate Advisory Board
Diverse Panel of Key Opinion Leaders to Share Expertise Across Company’s Therapeutic Focus Areas WESTLAKE VILLAGE, Calif. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to participate in a fireside chat at the BMO Capital Markets
Toggle Summary Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are pleased to report the results of our third quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis -- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are pleased to report the results of our second quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WESTLAKE VILLAGE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by
Toggle Summary Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Toggle Summary Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products
Toggle Summary Sienna Biopharmaceuticals Announces $40 Million Series B Financing
Topical Biotech Innovation in Medical Dermatology and Aesthetics WESTLAKE VILLAGE, Calif.--( BUSINESS WIRE )-- Sienna Biopharmaceuticals, Inc. , a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by
Toggle Summary Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Seasoned Executive Brings Experience from Medicis and Novan WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as
Toggle Summary Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
Appointment Marks Pyott's Return to Dermatology and Aesthetics WESTLAKE VILLAGE, Calif. , Feb. 28, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, is pleased to announce that David E.I.